GSK PLC GLAXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLAXF is a good fit for your portfolio.
News
-
Pfizer to Cut Stake in Haleon — Update
-
Pfizer to Cut Stake in Haleon to 24%
-
GSK's Endometrial Cancer Treatment Study Shows Combination Potential
-
Vir Biotechnology, GSK Terminate Collaboration on Flu
-
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk
-
23andMe shares slide more than 15% as lower services revenue hits Q3 results
-
Alector, GSK Get FDA Breakthrough Designation for Latozinemab
-
GSK Settles Another Zantac Case in California — Update
Trading Information
- Previous Close Price
- $19.54
- Day Range
- $19.85–19.85
- 52-Week Range
- $16.65–22.12
- Bid/Ask
- $19.59 / $22.09
- Market Cap
- $81.12 Bil
- Volume/Avg
- 769 / 1,702
Key Statistics
- Price/Earnings (Normalized)
- 10.30
- Price/Sales
- 2.16
- Dividend Yield (Trailing)
- 3.69%
- Dividend Yield (Forward)
- 5.07%
- Total Yield
- 3.69%
Company Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 70,200
- Website
- https://www.gsk.com
Competitors
Valuation
|
Metric
|
GLAXF
|
MRK
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.30 | 84.66 | 13.73 |
Price/Book Value | 4.64 | 8.56 | 1.60 |
Price/Sales | 2.16 | 5.38 | 2.44 |
Price/Cash Flow | 10.31 | 21.27 | 13.11 |
Price/Earnings
GLAXF
MRK
PFE
Financial Strength
|
Metric
|
GLAXF
|
MRK
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.59 | 0.68 | 0.58 |
Current Ratio | 0.88 | 1.25 | 0.91 |
Interest Coverage | 9.30 | 2.33 | 0.74 |
Quick Ratio
GLAXF
MRK
PFE
Profitability
|
Metric
|
GLAXF
|
MRK
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 10.54% | 3.59% | 4.98% |
Return on Equity (Normalized) | 50.48% | 9.12% | 10.90% |
Return on Invested Capital (Normalized) | 21.33% | 5.88% | 7.28% |
Return on Assets
GLAXF
MRK
PFE
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Zgvwmcst | Sqdgd | $689.2 Bil | |
JNJ
| Johnson & Johnson | Fpphhlj | Qys | $353.8 Bil | |
MRK
| Merck & Co Inc | Yvthzsg | Dctzt | $321.5 Bil | |
ABBV
| AbbVie Inc | Zvntkmr | Slqxq | $296.2 Bil | |
AZN
| AstraZeneca PLC ADR | Nrpzrgjk | Pnsg | $219.1 Bil | |
NVS
| Novartis AG ADR | Vffkdcjx | Jkzc | $200.8 Bil | |
RHHBY
| Roche Holding AG ADR | Khkzjhvgg | Gcfd | $196.3 Bil | |
AMGN
| Amgen Inc | Bdgslhcth | Xplr | $144.5 Bil | |
PFE
| Pfizer Inc | Zyjxgrmmc | Klp | $143.0 Bil | |
SNY
| Sanofi SA ADR | Fzlcmkvk | Pls | $117.2 Bil |